Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2025)
Historic Research & Development for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $14.0 million.
- Orchestra BioMed Holdings' Research & Development rose 2097.46% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 2971.69%. This contributed to the annual value of $42.8 million for FY2024, which is 2655.67% up from last year.
- According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Research & Development is $14.0 million, which was up 2097.46% from $13.9 million recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' Research & Development ranged from a high of $14.0 million in Q3 2025 and a low of $3.5 million during Q1 2022
- Moreover, its 4-year median value for Research & Development was $8.6 million (2023), whereas its average is $9.3 million.
- Its Research & Development has fluctuated over the past 5 years, first surged by 13759.36% in 2023, then surged by 1039.5% in 2024.
- Orchestra BioMed Holdings' Research & Development (Quarter) stood at $7.5 million in 2022, then increased by 12.83% to $8.5 million in 2023, then grew by 28.9% to $11.0 million in 2024, then increased by 27.86% to $14.0 million in 2025.
- Its last three reported values are $14.0 million in Q3 2025, $13.9 million for Q2 2025, and $13.5 million during Q1 2025.